RNA therapeutics have the potential to reach biological targets in ways that small molecules and antibodies cannot, and companies focused on these applications are on the verge of treating previously ‘undruggable’ diseases. Breakthroughs have come by focused research on RNA biology as well as the chemical modifications of underlying oligonucleotides to improve biophysical properties.
R&D teams working on RNA therapeutics require digital solutions that can design, develop, and experiment with molecules that leverage both biological and chemical properties. Yet this combination is not readily found in legacy software that was built only around small molecule or antibody workflows. A new approach is required to bring a common data foundation to RNA therapeutic development and to provide full traceability across sequences, chemical modifications, experiments, and process development.
RNA Therapeutics R&D Solution
Benchling’s RNA Therapeutics Solution was developed in partnership with leading industry innovators. For the first time, R&D teams can design chemically modified oligonucleotides, centralize experimental results, standardize on syntax, and collaborate with teammates more effectively on a single platform. Our modern, digital R&D solution combines the capabilities expected from in silico design tools, ELN, and LIMS into one modern, unified, fully-configurable, and easy-to-use solution that adapts to the rapidly evolving needs of RNA therapeutics R&D.
Our Customer Experience professionals possess deep scientific expertise as well as training on information technology best practices. They apply this know-how to support RNA therapeutic customers across a wide range of R&D teams.
Leverage Benchling's pre-implementation solutions consulting, professional implementation services, and customer success management expertise to help you get the most out of Benchling.
Take advantage of Benchling’s foundational implementation guides, developed by our Customer Experience team to support many RNA Therapeutic R&D functions.